Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
DUMMER, R; GORE, ME; HANCOCK, BW; GUILLOU, PJ; GROBBEN, HC; BECKER, JC; OSKAM, R; DIELEMAN, JP; BURG, G.
A MULTICENTER PHASE-II CLINICAL-TRIAL USING DACARBAZINE AND CONTINUOUS-INFUSION INTERLEUKIN-2 FOR METASTATIC MELANOMA - CLINICAL-DATA AND IMMUNOMONITORING
CANCER. 1995; 75(4): 1038-1044.
Doi: 10.1002/1097-0142(19950215)75:4<1038::AID-CNCR2820750421>3.0.CO;2-F
Web of Science
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Becker Jürgen Christian
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Background. Treatment of patients with metastatic melanoma with either dacarbazine or recombinant interleukin-2 (rIL-2) resulted in a response rate of approximately 15%. This study investigates the possible synergism of this chemoimmunotherapy combination. Methods. Fifty-seven patients with metastatic malignant melanoma received 135 treatment cycles. Treatment consisted of dacarbazine (Days 1-5) at 250 mg/m(2) by a 30-minute slow infusion, and interleukin-2 by constant intravenous infusion (Days 21-25 and 28-32) at 18 X 10(6) IU/m(2)/24 hours. After this treatment cycle, a 1-week rest was scheduled, and in the absence of undue toxicity or tumor progression, patients received a second cycle as described. Maximum treatment consisted of two induction and four maintenance cycles. In a subgroup of patients, immunoparameters were analyzed to identify prognostic factors. Standard supportive care was given. Results. Common toxicities included fever, hypotension, nausea/vomiting, anemia, leukopenia, thrombocytopenia, an increase in serum lactic dehydrogenase levels and diarrhea. The objective response rate was 15.8% (one complete response and eight partial responses). In 14 patients, the disease stabilized. For patients who had an objective response, median response duration was 13.9 months (6.3-39.0(+)), and median survival was 19.0 months (6.3-39.0(+)); overall survival was 9.3 months (0.8-39.0(+)). Immunomonitoring did not reveal any relevant prognostic factors for overall response. Conclusions. Sequential treatment with dacarbazine and rIL-2 is feasible and produces long-lasting responses in a minority of patients.
- Find related publications in this database (Keywords)
- METASTATIC MELANOMA
- TREATMENT
- DACARBAZINE
- INTERLEUKIN-2
- RESPONSE
- SURVIVAL
- PROGNOSTIC FACTORS